Pfizer Pledges $1.25B for Drug Candidate in Promising But Competitive Area of Immunotherapy

Pfizer Pledges $1.25B for Drug Candidate in Promising But Competitive Area of Immunotherapy

Pfizer is in-licensing a bispecific antibody drug for cancer that China-based 3SBio designed to block the proteins PD-1 and VEGF. The deal puts the pharmaceutical giant in a growing group of companies developing bispecific antibodies for those targets, many of them with molecules originally developed in China. The post Pfizer Pledges $1.25B for Drug Candidate in Promising But Competitive Area of Immunotherapy appeared first on MedCity News.